ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

2023.11.29
In recent years, there have been groundbreaking advancements in the exploration of treatment modalities for prostate cancer, particularly in the use of PARP inhibitors in combination with novel hormonal therapies, offering new hope for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The TALAPRO-2 study has demonstrated that the combination of talazoparib with enzalutamide significantly improves radiographic progression-free survival (rPFS) in the overall mCRPC patient population (HR=0.63; 95% CI, 0.51–0.78; P<0.0001) and in mCRPC patients with homologous recombination repair (HRR) gene defects (HR=0.45; 95% CI, 0.33–0.61; P<0.0001) compared to placebo in combination with enzalutamide[1]. As a result, the combination therapy of talazoparib and enzalutamide received FDA approval on June 20th of this year for first-line use in mCRPC patients with HRR gene mutations.
ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

2023.11.28
ADC drugs, also known as Antibody-Drug Conjugates, combine targeted antibodies with cytotoxic drugs to accurately attack tumor cells and minimize damage to normal cells. In recent years, ADC drugs have made significant breakthroughs in the field of cancer treatment and have become a focus of attention. At this year's ESMO conference, several studies on ADC drugs garnered significant attention. In this report, Professor Jian Zhang from Fudan University-affiliated Cancer Hospital introduces the progress in the treatment of breast cancer using ADC drugs.
The ESMO Congress 2023 has Successfully Concluded, and Ten Major Research Projects Have Bloomed at the Conference!

The ESMO Congress 2023 has Successfully Concluded, and Ten Major Research Projects Have Bloomed at the Conference!

2023.11.28
The ESMO Congress 2023, held from October 20th to 24th in Madrid, Spain, has concluded, marking a significant milestone in the field of oncology. With a central theme of "Disseminating innovative research for optimal cancer care," this year's event featured a unique blend of in-person and virtual components, uniting cancer researchers, clinicians, and experts from across the globe. The congress delivered cutting-edge research and unprecedented achievements across various areas of oncology. The notable achievements are particularly eye-catching in five main domains of oncology research, including Lung Cancer, Gynaecological Cancers, Genito-Urinary Cancers, Gastrointestinal Cancers, and Breast Cancer.
Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

Dr. Chun-rong Ju: Lung Transplant Recipients Receive Prolonged Contezolid Treatment for Nocardia InfectionDr. Chun-rong Ju: Lung Transplant Recipients

2023.11.28
Nocardia is a conditional pathogen, and infections are common in immunocompromised populations such as organ transplant recipients. Professor Chunrong Ju and her team at the First Affiliated Hospital of Guangzhou Medical University's Respiratory and Critical Care Department and Transplant Department previously reported cases of Nocardia infection in lung transplant recipients (LTR) among the East Asian population [1,2]. During the 2023 IDWeek congress, Dr. Chun-rong Ju further presented the clinical outcomes of 18 LTR Nocardia infection patients who received treatment with the novel oxazolidinone-class drugs Linezolid or Contezolid. The results indicated that these novel oxazolidinone drugs were effective during prolonged anti-infection therapy in such patients and had fewer toxic side effects, including bone marrow suppression [3].